Xenetic Biosciences Plunges 41% After All-Stock Santersus Acquisition
XBIO sits 19% above its 52-week low of $1.87 on elevated volume (18× avg).
Summary
Xenetic Biosciences announced a definitive all-stock acquisition of privately held Santersus AG, a therapeutic medical device company focused on selective blood purification targeting neutrophil extracellular traps (NETs). The deal is structured as a reverse merger, with Santersus holders owning approximately 85% of the combined entity, which will rebrand as Santersus Bio and trade under ticker SNTS. The market reacted sharply negative, with XBIO shares down 40.98% at $2.52 at publication, reflecting concerns over the highly dilutive nature of the transaction for existing Xenetic shareholders. The combined company plans to advance four clinical programs, including two FDA breakthrough device designations for sepsis and systemic lupus erythematosus. This follows the earlier ACCESS Newswire report of the acquisition, but the significant stock decline is new information that traders need to assess.
At the time of this announcement, XBIO was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $1.87 to $13.93. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.